Infectious disease
Eli Lilly and Company announced interim proof-of-concept data from its BLAZE-1 Phase II clinical trial of LY-COV555, its neutralizing antibody therapy for COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.
One company working towards an ARDS treatment is Athersys, a biotech company focusing on regenerative medicine therapies for diseases with significant unmet need.
Novavax and Serum Institute of India Private Limited (SIIPL) amended an agreement struck last month that will allow the company to double the number of doses of its experimental COVID-19 vaccine for potential use in 2021.
Only days after saying it expects to have key data from its Phase III clinical trial of its COVID-19 vaccine in October, Germany’s BioNTech received a grant of up to €375 million from the German Federal Ministry of Education and Research.
The United Arab Emirates has granted Emergency Use Authorization to an investigational vaccine for the novel coronavirus six weeks after late-stage studies began.
Although it is increasingly likely that one of the COVID-19 vaccines currently being tested will be approved or receive Emergency Use Authorization before the end of the year, experts are increasingly warning that widespread distribution may take a much longer time.
In a weekend interview on CBS’ “Face the Nation,” Albert Bourla, chief executive officer of Pfizer indicated they may have key data from its Phase III trial of the vaccine to the U.S. Food and Drug Administration by the end of October.
AstraZeneca resumed its vaccine testing in the United Kingdom following confirmation from the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
PRESS RELEASES